Additional Dosage Strengths Of Vyvanse Approved By FDA

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for three additional dosage strengths for the attention deficit hyperactivity disorder (ADHD) treatment, VYVANSE? (lisdexamfetamine dimesylate).

More: continued here

Filed under: ADHD on January 4th, 2008